Targets › PDE3
1 program from 1 company in 1 trial: 1 Phase 3; Respiratory; next expected readout Feb 2027.
Open in Phaseline: the race on PDE3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chia Tai Tianqing Pharmaceutical Group | TQC3721 Suspension for Inhalation Phosphodiesterase 3/4 (PDE3/4) inhibitor | PDE3, PDE4 | Phase 3 | Chronic Obstructive Pulmonary Disease | Feb 2027 |
Chronic Obstructive Pulmonary Disease (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.